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Abstract 
Background: Clinical trials of Chimeric Antigen Receptor (CAR) T cells manufactured from autologous peripheral 
blood mononuclear cell (PBMC) concentrates for the treatment of hematologic malignancies have been promising, 
but CAR T cell yields have been variable. This variability is due in part to the contamination of the PBMC concentrates 
with monocytes and granulocytes.
Methods: Counter-flow elutriation allows for the closed system separation of lymphocytes from monocytes and 
granulocytes. We investigated the use of PBMC concentrates enriched for lymphocytes using elutriation for manufac-
turing 8 CD19- and 5 GD2-CAR T cell products.
Results: When compared to PBMC concentrates, lymphocyte-enriched elutriation fractions contained greater pro-
portions of CD3+ and CD56+ cells and reduced proportions of CD14+ and CD15+ cells. All 13 CAR T cell products 
manufactured using the elutriated lymphocytes yielded sufficient quantities of transduced CAR T cells to meet clinical 
dose criteria. The GD2-CAR T cell products contained significantly more T cells and transduced T cells than the CD19-
CAR T cell products. A comparison of the yields of CAR T cells produced from elutriated lymphocytes with the yields 
of CAR T cells previous produced from cells isolated from PBMC concentrates by anti-CD3/CD28 bead selection or by 
anti-CD3/CD28 bead selection plus plastic adherence found that greater quantities of GD2-CAR T cells were produced 
from elutriated lymphocytes, but not CD19-CAR T cells.
Conclusions: Enrichment of PBMC concentrates for lymphocytes using elutriation increased the quantity of GD2-
CAR T cells produced. These results provide further evidence that CAR T cell expansion is inhibited by monocytes and 
granulocytes.
Keywords: Chimeric antigen receptor T cells, Cancer immunotherapy, Cellular therapy, T cells, Elutriation, Myeloid 
derived suppressor cells, Peripheral blood mononuclear cells
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Background
Early phase clinic trials of T cells genetically engineered 
to express chimeric antigen receptors (CAR) have been 
encouraging. CD19-CAR T cells have been used suc-
cessfully in a number of clinical trials to treat non-Hodg-
kin lymphoma and acute lymphocytic leukemia (ALL) 
[1–8]. Preliminary studies of B cell maturation antigen 
(BCMA)-CAR T cells to treat multiple myeloma have 
also been promising [9].
Most CAR T cell manufacturing protocols initate cell 
production with autologous T cells collected by apher-
esis using a blood cell separator which separates lympho-
cytes from plasma, platelets, red blood cells (RBCs) and 
granulocytes. However, the lymphocyte-rich peripheral 
blood mononuclear cell (PBMC) concentrates collected 
by apheresis are also enriched for monocytes and contain 
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The quantities of these contaminating cells are depend-
ent on the type of blood cell separator and how the blood 
cell separator is operated. The composition of the PBMC 
concentrates are also dependent on the type of tumor 
(solid vs. liquid), and the patient’s blood counts at the 
time of collection [10]. While the quantities of these con-
taminating RBCs, platelets and granulocytes cells can be 
minimized with highly trained users of the cell separa-
tor instrument, they cannot be completely eliminated. 
Consequently, prior to beginning the CAR T cell manu-
facturing process the PBMC concentrates are generally 
enriched for lymphocytes or CD3+ cells in the cell pro-
cessing laboratory.
Our center initially manufactured CD19- and GD2-
CAR T cells using autologous PBMC concentrates 
enriched for T cells by magnetic selection with the 
anti-CD3/CD28 beads. These same anti-CD3/CD28 
beads were also used to stimulate T cell expansion. 
While the method was, in general, effective, we found 
that the quantities of GD2-CAR T cells produced were 
less than the quantities of CD19-CAR T cells produced 
[11]. In addition, CAR T cells from some patients failed 
to expand to sufficient levels to meet patient treatment 
dose criteria. Upon further investigation, we discovered 
that the presence of large quantities of monocytes or 
granulocytes in some PBMC concentrates was associ-
ated with poor in  vitro expansion of CAR T cells [11]. 
We modified the T cell enrichment method to include 
a plastic adherence step to deplete PBMC concentrates 
of monocytes prior to the anti-CD3/CD28 bead enrich-
ment step. This modified T cell enrichment process 
improved T cell expansion, but it was not completely 
effective at removing contaminating monocytes and 
granulocytes and did not completely eliminate manu-
facturing failures [11].
We hypothesized that more rigorous enrichment of 
the starting material for lymphocytes would improve the 
yield of transduced T cells and reduce the incidence of 
manufacturing failures. A semi-automated counter-flow 
elutriation instrument is available for enriching PBMC 
concentrates for monocytes and lymphocytes which 
makes use of a sterile single use disposable kit [12].
We modified our CAR T cell manufacturing process 
to include elutriation for the enrichment of PMBC con-
centrates for lymphocytes rather than anti-CD3/CD28 
bead selection or anti-CD3/CD28 bead selection plus 
plasitic adherence. We report the results of manufac-
turing CD19- and GD2-CAR T cells using lymphocytes 
collected by apheresis and enriched by elutriation as 
starting material. We also compared CD19- and GD2-
CAR T cells manufactured from elutriated lymphocytes 
with those that we previously manufactured from PBMC 
concentrates that were enriched for lymphocytes with 




Patients in this study were enrolled in an open-label 
phase 1 dose-escalation study of CD19-CAR T cells in 
children and young adults with ALL or non-Hodgkin 
lymphoma, NCT01593696, or an open-label phase 1 
dose-escalation study of GD2-CAR T cell in children and 
young adults with GD2 expressing osteosarcoma or neu-
roblastoma, NCT02107963. Clinical results of the first 21 
of the patients receiving CD19-CAR T cell therapy have 
previously been reported [1]. The results of CD19-CAR 
T cell manufacturing from the first 43 patients and GD2-
CAR T cells from the first 11 patients have previous been 
reported [11]. This study reports the results of manufac-
turing CD19-CAR T cells from 8 additional patients and 
GD2-CAR T cells from 5 additional patients. Among the 
8 patients treated with CD19-CAR T cells 7 had ALL and 
one had diffuse large B cell lymphoma (DLBCL). All 5 
patients treated with GD2-CAR T cells all had osteosar-
coma. All 8 patients receiving CD19-CAR T cells were 
given a dose of 1  ×  106  cells/kg and 2 patients receiv-
ing GD2-CAR T cells were given a dose of 3 × 106 CAR 
T cells/kg and 3 patients were given a dose of 1  ×  107 
CAR T  cells/kg. All subjects were enrolled in protocols 
approved by the National Cancer Institute (NCI) Institu-
tional Review Board and inform consent was obtained.
We also compared the results of manufacturing CD19- 
and GD2-CAR T cells in this study with the previously 
reported results of manufacturing CD19- and GD2-CAR 
T cells using PBMC concentrates enriched for T cells by 
selection with anti-CD3/CD28 beads with and without 
plastic adherence [11].
Manufacturing CAR T cells
Peripheral blood mononuclear cells concentrates were 
collected using a blood cell separator (Cobe Spectra, Ter-
umo BCT, Lakewood, CO, USA) and 10–15  L of blood 
was processed. CD19-CAR T cells were manufactured 
from PBMC concentrates using a modification of the 
method we previously described [11, 13]. When PBMCs 
were enriched for lymphocytes by anti-CD3/CD28 bead 
selection, on day 0, a fresh or cryopreserved PBMC 
concentrate containing 600  ×  106 CD3+  cells were 
enriched for CD3+ cells using anti-CD3/CD28 antibod-
ies bound to paramagnetic beads (Dynabeads ClinExVivo 
CD3/CD28, Invitrogen, Camarillo, CA) at a ratio of 3:1 
(beads:cells). The cells and beads were co-incubated for 
2 h at room temperature and CD3+ cell enrichment was 
performed using Dynal ClinExVIVO MPC magnet (Inv-
itrogen, Camarillo, CA). A total of 100 × 106 cells in the 
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CD3+  fraction were resuspended at a concentration of 
1  ×  106 cells/mL in PermaLife bags (OriGen Biomedi-
cal, Austin, TX) at 37  °C in 5% CO2 in AIM V medium 
(Gibco, Grand Island, NY), supplemented with 5% heat-
inactivated human AB Serum (Valley Biomedical, Win-
chester, VA), 1% Gluta-Max (Gibco, Grand Island, NY), 
40  IU/mL IL-2 (Novartis Vaccines and Diagnostics, Inc. 
Emeryville, CA).
For manufacturing CD19-CAR T cells, the lympho-
cyte enriched cells were transduced twice with clinical 
grade MSGV-FMC63-28Z recombinant retroviral vec-
tor supernatant, once on day 2 and once on day 3, in 
retronectin-coated bags. The cells were maintained in 
culture for 7–9  days. The cell concentration was main-
tained at 0.4 × 106 cells/mL by adding fresh media every 
other day. On the day of harvest the anti-CD3/CD28 
paramagnetic beads were removed using the Dynal 
ClinExVIVO MPC magnet (Invitrogen, Camarillo, CA), 
washed, concentrated and quality control assessment 
was performed.
For manufacturing GD2-CAR T cells, the same lym-
phocyte enrichment processes was used and a similar 
process was used to transduce and expand the cells. Cells 
were transduced once on day 2 with anti-GD2.28.z.OX40.
ICD9 retroviral vector supernatant and were harvested 
after 10 or 11 days in culture.
When PBMC concentrates were enriched for lym-
phocytes by anti-CD3/CD28 bead selection plus plastic 
adherence the PBMC concentrates were incubated with 
anti-CD3/CD28 beads for 2 h in T flasks rather than in 
bags. At the end of the 2  h incubation period the non-
adherent cells were collected and the cells were processed 
as described above.
When the PBMC concentrates were enriched for lym-
phocytes by elutriation they were subject to elutriation 
using a semi-automatic counter-flow elutriation instru-
ment (Elutra Cell Separation System, version 1.1, Terumo 
BCT) using a user defined profile which collects cells in 
5 fractions. The chamber rotation speed was maintained 
at 2400 RPMs for fractions 1 through 4 and the media 
flow rate was maintained at 60  mL/min for fraction 1, 
120  mL/min for fraction 2, 122  mL/min for fraction 3 
and 124 mL/min for fraction 4. Fraction 5 was the cells 
remaining in the chamber and they were collected with 
the rotor turned off. Lymphocytes were found in frac-
tions 1 and 2 and monocytes and granulocytes were in 
fraction 5. Fraction 1 and 2 also were enriched with plate-
lets and RBCs [12].
The lymphocyte fraction was depleted of RBCs by lysis. 
The cells were pelleted by centrifugation, incubated for 
7–10 min with ACK Lysing Buffer (Lonza, Walkersville, 
MD) and then washed and resuspended in 0.9% saline 
(B.Braun Medical Inc., Irvine, CA) with 0.3% trisodium 
citrate (TriCitrasol anticoagulant sodium citrate concen-
trate 46.7%, Citra Labs, Braintree, MA).
Cell counts and flow cytometry
Blood counts were measured using automated hematol-
ogy analyzer (Cell-Dyn 3700). Flow cytometry was per-
formed with a FACSCanto II (BeckinDickinson) using 
CD3, CD4, CD8, CD14, CD15, CD19, CD45 and CD56 
antibodies (BD Biosciences, San Jose, CA). The expres-
sion of CD19-CAR and GD2-CAR was assessed by flow 
cytometry with anti-idiotype antibodies.
Statistically analysis
The values shown are mean  ±  1 standard deviation 
unless otherwise indicated. Groups were compared using 
t-tests (Microsoft Excel, Microsoft Inc., Redmond, WA).
Results
Composition of the PBMC concentrates and elutriated 
lymphocytes
We manufactured 8 CD19 CAR T cell products and 5 
GD2-CAR T cell products using autologous PBMC con-
centrates collected by apheresis and enriched for lym-
phocytes by elutriation. The PBMC concentrates, as 
expected, contained significant quantities of monocytes 
and neutrophils in addition to the desired lymphocytes 
(Table 1).
To assess the effectiveness of elutriation for lymphocyte 
enrichment the PBMC concentrates and the elutriated 
lymphocyte fractions were analyzed by flow cytometry 
with anti-CD3, anti-CD19, anti-CD14, anti-CD15 and 
anti-CD56 for T cells, B cells, monocytes, neutrophils and 
NK cells, respectively (Table 2). Among all of the proce-
dures analyzed the elutriated lymphocytes were enriched 
for CD3+ cells and CD56+ cells and had reduced levels 
of CD14+ and CD15+ cells. There was no difference in 
the proportion of CD19+ cells in the PBMC concentrates 
and lymphocytes fraction. The elutriated lymphocytes 
from patients enrolled in both the CD19- and GD2-
CAR T cell protocols contained a greater proportion 
Table 1 Proportion of  leukocytes in  autologous PBMC 
concentrates collected for CD19- and GD2-CAR T cell man-
ufacturing
a Values represent the mean ± SD and range
Cell type CAR T cell type
n CD19 (n = 8) GD2 (n = 5) All (n = 13)
Neutrophils (%) 11.0 ± 18.2 
(1–58)a
5.2 ± 3.6 (1–10) 8.8 ± 14.4 
(1–58)
Lymphocytes (%) 59.1 ± 24.1 
(7–84)
65.8 ± 6.8 
(58–78)
61.7 ± 24.7 
(7–89)
Monocytes (%) 27.1 ± 12.3 
(8–45)
26.4 ± 6.2 
(19–38)
26.8 ± 12.2 
(8–45)
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of CD3+  and less CD14+  cells than the PBMC con-
centrates. The lymphocyte fraction from CD19-CAR T 
patients was also enriched for CD56+ cells.
Manufacturing CD19‑ and GD2‑CAR T cells using elutriated 
lymphocytes
All 13 CAR T cell manufacturing procedures yielded 
sufficient quantities of T cells to meet the dose crite-
ria (1  ×  106/kg for CD19-CAR T cells and 3  ×  106 or 
1 × 107 cells/kg for GD2-CAR T cells). The 13 CAR T cell 
products contained 2166 ± 1113 × 106 CD3+ cells and 
1064 ± 877 × 106 transduced CD3+ T cells. The GD2-
CAR T cell final products contained more total nucleated 
cells (TNC), CD3+ cells and transduced CD3+ cells than 
the CD19-CAR T cell final products (Table 3). There was 
no difference among CD19- and GD2-CAR T cell final 
products in the proportion of CD3+ cells or transduced 
CD3+  cells (Table  3). The proportion of CD3+  cells 
that expressed CD4 or CD8 was also similar among 
CD19- and GD2-CAR T cell final products (Table  3). 
The proportion of CD19+  cells was also measured in 
the CD19-CAR T cell final products and very few were 
detected, 0.1 ± 0.1%, range = 0.0–0.2%.
Comparison of CAR T cells manufactured using 
lymphocytes enriched by anti‑CD3/CD28 bead selection 
with and without plastic adherence and elutriation
We compared the yields of CAR T cells produced from 
PBMC concentrates enriched for lymphocytes by elutri-
ation in this study and those produced from PBMC con-
centrates enriched for lymphocytes by anti-CD3/CD28 
beads with and without plasitic adherence in a previ-
ous study [11]. For GD2-CAR T cell products, greater 
quantities  of T cells were produced from elutriated 
lymphocytes (4119 ±  934 ×  106) than from anti-CD3/
CD8 bead enriched (183 ± 106 × 106; p = 6.73 × 10−6) 
and anti-CD3/CD28 bead plus adherence enriched 
cells (1404  ±  1136  ×  106; p  =  6.14  ×  10−3) (Fig.  1a) 
and greater quantities of CD3+  transduced GD2-
CAR T cells were produced from elutriated lympho-
cytes (1940  ±  775  ×  106) than from anti-CD3/CD28 
bead enriched (147 ± 102 × 106; p = 6.68 × 10−4) and 
Table 2 Comparison of the composition of PBMC concentrates and the elutriated lymphocyte fraction used to manufac-
ture CD19- and GD2-CAR T cells
a p < 0.05 Paired T-tests of pre- and post-elutriation samples
Values represent the mean ± SD
Cell type CAR T cell type
CD19 GD2 All
n PBMC Elutriated lymphs n PBMC Elutriated Lymphs n PBMC Elutriated lymphs
CD3+ 8 49.0 ± 23.1 62.1 ± 24.4a 5 42.2 ± 17.0 58.0 ± 23.0a 13 49.3 ± 22.5 64.6 ± 25.5a
CD14+ 8 17.2 ± 11.4 3.5 ± 1.7a 4 20.9 ± 9.7 3.9 ± 3.2a 12 19.9 ± 13.7 3.6 ± 4.8a
CD15+ 8 8.2 ± 15.2 4.1 ± 10.6 4 3.9 ± 2.8 0.8 ± 1.4 12 6.9 ± 12.0 2.9 ± 8.2a
CD19+ 8 13.8 ± 16.9 13.4 ± 16.4 2 10.4 ± 6.7 14.5 ± 9.2 10 14.0 ± 14.7 11.9 ± 8.6
CD56+ 8 7.4 ± 4.9 12.6 ± 8.5a 2 4.8 ± 2.8 6.8 ± 3.8 10 7.2 ± 5.0 11.9 ± 8.6a
Table 3 Quantity of  total nucleated cells, CD3+  cells and  transduced CD3+  cells in  the final CAR T cell products 
and CD4+ and CD8+ cell content of the final products
a p < 0.05 for comparison of CD19- and GD2-CAR T cells
Cell type CAR T cell type
CD19 (n = 8) GD2 (n = 5) All (n = 13)
Mean ± SD Range Mean ± SD Range Mean ± SD Range
TNC (×106) 981 ± 235 668–1440 4384 ± 1194a 2250–6610 2289 ± 1865 668–6160
CD3+ cells (×106) 946 ± 273 500–1434 4119 ± 934a 2499–5119 2166 ± 1133 500–5119
Transduced CD3+ cells (×106) 517 ± 223 150–763 1940 ± 775a 837–3018 1064 ± 877 150–3018
CD3+ cells (%) 95.4 ± 8.6 74.9–99.9 95.1 ± 6.0 83.1–98.7 95.3 ± 25.5 74.9–99.9
Transduced CD3+ cells (%) 52.8 ± 15.0 30.0–69.3 45.7 ± 12.0 33.5–63.7 50.1 ± 21.3 30.0–69.3
CD4+ cells (%) 50.6 ± 14.8 24.9–72.3 38.1 ± 17.2 14.1–57.1 45.8 ± 19.7 14.1–72.3
CD8+ cells (%) 42.4 ± 16.5 18.3–65.7 53.3 ± 15.2 35.3–74.1 45.6 ± 19.6 18.3–74.1
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anti-CD3/CD28 bead plus adherence enriched cells 
(576 ± 437 × 106; p = 0.015) (Fig. 1b). For CD19-CAR 
T cells, greater quantities of T cells were produced 
from elutriated lymphocytes (946  ±  273  ×  106) than 
from anti-CD3/CD28 bead enriched (305 ± 280 × 106; 
p  =  8.34  ×  10−4) and bead plus adherence enriched 
cells (577  ±  284  ×  106; p  =  6.04  ×  10−3) (Fig.  2a), 
but the quantities of transduced T cells were no 
greater from elutriation enriched lymphocytes 
(517  ±  223  ×  106) than from anti-CD3/CD28 bead 
enriched (253 ± 227 × 106; p = 0.052) or beads selec-
tion plus adherence enriched cells (410  ±  183  ×  106; 
p = 0.223) (Fig. 2b). 
There was no difference in transduction efficien-
cies of T cells among the GD2-CAR T cells manufac-
tured using PBMC concentrates enriched by elutriation 
and bead selection plus adherence (45.7  ±  12.0 versus 
42.6  ±  22.5%; p  =  0.81); both were transduced once. 
GD2-CAR T cells manufactured with cells enriched 
by anti-CD3/CD28 bead selection alone were trans-
duced twice and the transduction efficiency was greater 
(75.1  ±  14.6%) than those manufactured with cells 
enriched by elutriation (p = 9.70 × 10−3) and beads plus 
adherence (p  =  0.0283). All CD19-CAR T cell prod-
ucts were transduced twice but the transduction effi-
ciencies were less for CD19-CAR T cells manufactured 
using elutriation enriched cells than anti-CD3/CD28 
bead plus adherence enriched cells (52.8  ±  15.0 versus 
72.7 ±  12.1%; p =  1.9 ×  10−3) but not anti-CD3/CD28 
bead enriched cells (76.4 ± 26.6%; p = 0.055).
We also compared the CD4 and CD8 composition of 
CAR T cells manufactured from lymphocytes enriched 
using the 3 different methods and found no difference 
in the proportion of CD3+ cells that expressed CD4 and 
CD8 among CAR T cells manufactured from PBMCs 
enriched for lymphocytes or T cells using the 3 different 
methods (Table 4).
Discussion
We investigated manufacturing CAR T cells using autol-
ogous PBMC concentrates enriched for lymphocytes 
using counter flow elutriation. The number of clinical 
products analyzed was relatively small, but we found that 
elutriation was effective at enriching autologous PBMC 


















































Fig. 1 Quantity of T cells and transduced T cells in GD2-CAR T cell products. GD2-CAR T cells were manufactured over 10 or 11 days using autolo-
gous PBMC concentrates enriched for lymphocytes using one of 3 methods: anti-CD3/CD28 bead selection (n = 6, circles), anti-CD3/CD28 bead 
selection plus plastic adherence (n = 5, triangle) and elutriation (n = 5, diamonds). The quantity of CD3 + cells in the final product is shown in a and 
transduced CD3+ cells in b
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When compared to methods that we have previous 
used to enrich PBMC concentrates for T cells or lympho-
cytes, anti-CD3/CD28 bead selection and bead selection 
plus plastic adherence, beginning manufacturing with 
elutriated lymphocytes resulted in greater T cell yields. 
Furthermore, the yield of T cells transduced with GD2-
CAR was greatest when manufacturing was initiated 
with elutriated lymphocytes, but this was not the case 
with CD19-CAR T cell products. While the overall T cell 
yields for CD19-CAR T cell products was greatest when 
manufacturing was initiated with elutriated lymphocytes, 
the CD19-CAR T cell transduction efficiency was less for 
the cells produced from elutriated lymphocytes and there 
was no significant increase in the yield of transduced 
CD19 CAR T cells.
Among the 13 CD19- and GD2-CAR T cells products 
manufactured using elutriated lymphocytes, all products 
contained enough transduced T cells to meet protocol 
dose requirements. We have previously found that CAR 
T cells manufactured using T cells selected with anti-
CD3/CD28 beads failed to contain sufficient quantities of 
transduced CD3+ cells to meet protocol dose criteria in 
4 of 28 CD19-CAR T cell patients and none of 6 GD2-
CAR T cell patients [11]. A change in the manufactur-
ing process to include a monocyte depletion step using 




















































Fig. 2 Quantity of T cells and transduced T cells in CD19-CAR T cell products. CD19-CAR T cells were manufactured over 7–9 days using autologous 
PBMC concentrates enriched for lymphocytes using one of 3 methods: anti-CD3/CD28 bead selection (n = 6, circles), anti-CD3/CD28 bead selec-
tion plus plastic adherence (n = 16, triangle) and elutriation (n = 8, diamonds). The quantity of CD3+ cells in the final product is shown in a and 
transduced CD3+ cells in b
Table 4 Comparison of  the portion of  CD4+  and CD8+  cells in  CAR T cells manufactured from  PBMC concentrates 
enriched for lymphocytes using 3 different methods
Lymphocyte enrichment method CAR T cell type
CD19 GD2
n CD4 CD8 n CD4 CD8
Anti-CD3/CD28 beads 6 54.5 ± 26.1 35.0 ± 25.1 6 45.8 ± 12.3 48.4 ± 14.7
Anti-CD3/CD28 beads + plastic adherence 16 57.3 ± 15.7 38.4 ± 14.8 5 48.0 ± 48.7 40.0 ± 10.1
Elutriation 8 50.6 ± 14.8 42.4 ± 16.5 5 38.1 ± 17.1 53.2 ± 15.1
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did not meet dose criteria to 1 of 20 patients; none of 15 
CD19-CAR T cell products and to 1 of 5 GD2-CAR T cell 
products [11].
The finding that beginning manufacturing with elutri-
ated lymphocytes improved GD2-CAR T cell expansion 
more than CD19-CAR T cells is likely due to the pres-
ence of greater quantities of myeloid cells in autologous 
PBMC concentrates used to manufacture GD2-CAR T 
cells. Most patients treated with GD2-CAR T cells had 
osteosacrcoma who are known to have circulating mye-
loid-derived suppressor cells (MDSCs) [14]. The patients 
treated in this study with CD19-CAR T cells most often 
had ALL and patients with hematologic malignancies are 
less likely to have circulating MDSCs [15, 16].
One limitation of the use of elutriation to isolate lym-
phocytes for CAR T production is that the elutriated 
lymphocyte fraction not only contains T cells, but it 
also contains B cells and NK cells and RBCs. A portion 
of acute lymphocyte leukemia blast cells are also found 
in the lymphocyte fraction. While we continue to initiate 
GD2-CAR T cell manufacturing with elutriated lympho-
cytes, we are investigating other, more specific methods 
of T cell purification for manufacturing CAR T cells for 
patients with ALL in order to improve T cell expansion 
and to exclude leukemic cells from being transduced.
Conclusions
We found that counter flow elutriation of PBMC con-
centrates collected from children and young adults with 
ALL and sarcoma produced lymphocyte fractions with 
reduced quantities of neutrophils and monocytes. CAR 
T cells can be consistently produced and expanded from 
elutriated lymphocytes. These results provide further 
evidence of the importance of beginning CAR T cell 
manufacturing with lymphocytes that contain few con-
taminating myeloid cells.
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